Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 + Talazoparib in Advanced Solid Tumors
NCT03875313Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in solid tumor, clear cell renal cell carcinoma (ccRCC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), sponsored by Calithera Biosciences. Started May 2019; status: terminated.
02
Drugs
telaglenastat
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03875313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875313.